Arrowhead Expands Management Team with Appointment of Susan Boynton as Vice President Global Regulatory Affairs
30 September 2014 - 9:30PM
Business Wire
Arrowhead Research Corporation (NASDAQ: ARWR), a
biopharmaceutical company developing targeted RNAi therapeutics,
today announced that Susan Boynton has been appointed Vice
President, Global Regulatory Affairs. In this role, Ms. Boynton
will have overall leadership responsibilities to direct the
Company's regulatory initiatives and strategy, and to ensure
appropriate regulatory compliance in the conduct of all Arrowhead
development programs and required reporting to the FDA and
international health authorities.
“Susan is an accomplished leader and we are excited to have her
join the Arrowhead management team,” said Christopher Anzalone,
Ph.D., Arrowhead’s President and Chief Executive Officer. “Her
experience leading regulatory efforts through the development and
commercialization process will be extremely valuable to Arrowhead
as we move ARC-520 and ARC-AAT forward and, importantly, as we
continue to expand our pipeline of RNAi therapeutics.”
Susan Boynton is an accomplished regulatory affairs professional
with 30 years of experience developing successful regulatory
strategies, leading global filings, and ensuring regulatory
compliance in the U.S., EU, and other major markets. Ms. Boynton
comes to Arrowhead from Shire where she served as Vice President,
Head of Regulatory Affairs, North America and Global Policy and
Intelligence. In this capacity she was responsible for leadership
and direction of North America regulatory staff supporting all
Shire business units. As part of Shire Human Genetic Therapies, she
also previously led all regional regulatory functions including
operations, CMC, promotion, and labeling. Prior to her role at
Shire, Ms. Boynton held leadership positions in regulatory affairs
at Amgen, Abbott Laboratories, Sanofi, and Novartis in the U.S. and
in Europe. Ms. Boynton earned a Bachelor of Science in Pharmacology
with Honors from Sunderland University, U.K., a Graduate Diploma in
Law from College of Law of England and Wales, and a Masters of
Jurisprudence, Health Law from Beasley Institute of Health Law and
Policy, School of Law, Loyola University, Chicago.
About Arrowhead Research Corporation
Arrowhead Research Corporation is a biopharmaceutical company
developing targeted RNAi therapeutics. The company is leveraging
its proprietary Dynamic Polyconjugate delivery platform to develop
targeted drugs based on the RNA interference mechanism that
efficiently silences disease-causing genes. Arrowhead’s pipeline
includes ARC-520 for chronic hepatitis B virus, ARC-AAT for liver
disease associated with Alpha-1 antitrypsin deficiency, and
partner-based programs in obesity and oncology.
For more information please visit
http://www.arrowheadresearch.com, or follow us on Twitter
@ArrowRes. To be added to the Company's email list and receive news
directly, please visit
http://ir.arrowheadresearch.com/alerts.cfm.
NASDAQ Notice
As an inducement to entering into employment with the Company,
on September 29, 2014, Ms. Boynton was awarded "inducement" options
and restricted stock units (RSU) under Rule 5635(c)(4) of the
NASDAQ Marketplace Rules. The option entitles Ms. Boynton to
purchase, outside of the Company's stockholder approved equity
incentive plans, an aggregate of up to 20,000 shares of the
Company's common stock at an exercise price per share of $15.05,
the last reported closing price of the Company's common stock on
the date of grant. The option vests and becomes exercisable over a
period of four years from the date of grant. Ms. Boynton was also
awarded 40,000 RSUs that vest annually in three equal
installments.
Arrowhead Research CorporationVince Anzalone, CFA,
626-304-3400ir@arrowres.comorInvestor Relations:The Trout
GroupLauren Glaser, 646-378-2972ir@arrowres.comorMedia:Russo
PartnersMartina Schwarzkopf, Ph.D.,
212-845-4292martina.schwarzkopf@russopartnersllc.com
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From Apr 2024 to May 2024
Arrowhead Pharmaceuticals (NASDAQ:ARWR)
Historical Stock Chart
From May 2023 to May 2024